Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA.
Placental malaria is a major health problem for both pregnant women and their fetuses in malaria endemic regions. It is triggered by the accumulation of Plasmodium falciparum-infected erythrocytes (IE) in the intervillous spaces of the placenta and is associated with foetal growth restriction and ma...
Main Authors: | Sisse B Ditlev, Raluca Florea, Morten A Nielsen, Thor G Theander, Stefan Magez, Philippe Boeuf, Ali Salanti |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24465459/?tool=EBI |
Similar Items
-
Several domains from VAR2CSA can induce <it>Plasmodium falciparum </it>adhesion-blocking antibodies
by: Theander Thor G, et al.
Published: (2010-01-01) -
Identification and characterization of B-cell epitopes in the DBL4ε domain of VAR2CSA.
by: Sisse B Ditlev, et al.
Published: (2012-01-01) -
Identification of glycosaminoglycan binding regions in the <it>Plasmodium falciparum </it>encoded placental sequestration ligand, VAR2CSA
by: Theander Thor G, et al.
Published: (2008-06-01) -
A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA.
by: Susan Thrane, et al.
Published: (2015-01-01) -
Differential induction of functional IgG using the Plasmodium falciparum placental malaria vaccine candidate VAR2CSA.
by: Vera V Pinto, et al.
Published: (2011-03-01)